LearnGlossaryMarketStocksSuperinvestorsSign in

SRPT

Sarepta Therapeutics, Inc.

Healthcare · $2.0B market cap

Verdict

We can't put a fair value on SRPT right now. Its earnings are too small compared with its share price for an earnings-based value to mean anything.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth9.2% a year✗
Sales growth33.1% a year✓
Free cash flow growth—?
Return on invested capital-10.9%✗

Follow SRPT

Track it on your watchlist and see the full analysis. Free.

Create a free account

Superinvestors

1 of the investors we track holds SRPT. In Q2 2026, 1 opened a position. Who we track

Howard Marks

Oaktree Capital Management · as of Q2 2026

$6.3B

6,709,000 shares

Moves in Q2 2026

New position: Howard Marks

Insider activity

Since Sep 4, 2026: no open-market purchases and 4 other filings (stock awards, tax withholding and similar). Why purchases matter

Other filings

Rodino-Klapac Louise

President, R&D and Tech Ops · 2026-09-04

Tax withholding

$476K

Rothfuss Cristin

EVP, General Counsel · 2026-09-04

Tax withholding

$489K

Estepan Ian Michael

Chief Operating Officer · 2026-09-04

Tax withholding

$551K

Wong Ryan Ho-Yan

Chief Financial Officer · 2026-09-04

Tax withholding

$295K

About Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company currently offers two approved treatments: EXONDYS 51, prescribed for Duchenne muscular dystrophy (DMD) patients with confirmed dystrophin gene mutations amenable to…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works